# TAR-210 (NCT05567185)

> A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05567185
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Pharmaceutical K.K.
- Conditions: Urinary Bladder Neoplasms; Receptors, Fibroblast Growth Factor
- Interventions: Erdafitinib Intravesical Delivery System
- Enrollment: 5
- Primary outcome: Number of Participants with Dose-limiting Toxicity (DLT)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 4
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=tar-210-nct05567185